NICODERM CQ Drug Patent Profile
✉ Email this page to a colleague
When do Nicoderm Cq patents expire, and what generic alternatives are available?
Nicoderm Cq is a drug marketed by Chattem Sanofi and is included in one NDA.
The generic ingredient in NICODERM CQ is nicotine. There are thirty drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the nicotine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nicoderm Cq
A generic version of NICODERM CQ was approved as nicotine by AVEVA on October 20th, 1997.
Summary for NICODERM CQ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 35 |
| Patent Applications: | 4,748 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NICODERM CQ |
| DailyMed Link: | NICODERM CQ at DailyMed |
See drug prices for NICODERM CQ
Recent Clinical Trials for NICODERM CQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Southern California | Phase 1 |
| National Cancer Institute (NCI) | Phase 1 |
| GlaxoSmithKline | Phase 1 |
Pharmacology for NICODERM CQ
| Drug Class | Cholinergic Nicotinic Agonist |
Anatomical Therapeutic Chemical (ATC) Classes for NICODERM CQ
Paragraph IV (Patent) Challenges for NICODERM CQ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| NICODERM CQ | Transdermal System | nicotine | 7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs | 020165 | 1 | 2014-05-30 |
US Patents and Regulatory Information for NICODERM CQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-006 | Aug 2, 1996 | OTC | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-005 | Aug 2, 1996 | OTC | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-004 | Aug 2, 1996 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NICODERM CQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-004 | Aug 2, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-005 | Aug 2, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-005 | Aug 2, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | NICODERM CQ | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020165-006 | Aug 2, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NICODERM CQ
See the table below for patents covering NICODERM CQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 297690 | ⤷ Try a Trial | |
| Australia | 630614 | ⤷ Try a Trial | |
| Denmark | 175805 | ⤷ Try a Trial | |
| Australia | 666208 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
